Stargardt Disease

Leading form of inherited macular degeneration

Stargardt Disease (STGD1) is a rare, progressive, and serious genetic disease that almost universally leads to legal blindness. Onset of vision loss typically starts in childhood or adolescence. Although rare, it affects approximately 60,000 people in the United States and is the 3rd largest monogenic recessive disease. Currently, there is no available treatment for Stargardt Disease.

Patients with STGD1 most often experience loss of visual acuity that is uncorrectable by glasses and/or vision aids during their childhood and teenage years. Diagnosis is often delayed due to lack of understanding and awareness of the disease, complicating treatment options and outcomes.

STGD commonly affects central vision and causes an atrophy in the macula , while sparing some peripheral vision. Majority of STGD1 patients will live legally blind for most of their adulthood. Loss of central vision and legal blindness limits patients from performing certain tasks like reading, writing, driving, and recognizing faces. There are some patients with a late-onset form of STGD1 that do retain some visual acuity in adulthood. The ABCA4 gene, which was implicated in the pathophysiology of STGD1 in 1997, is responsible for the synthesis of a protein that transports vitamin A molecules from light sensitive molecules called “photoreceptors” into specialized cells that are part of the “RPE ” so that vitamin A can be recycled/reused for vision.

In STGD1, defects in the ABCA4 gene lead to partially or fully dysfunctional Rim proteins. Such dysfunction negatively affects transportation and recycling of vitamin A, causing an accumulation of vitamin A that eventually leads to formation of toxic “vitamin A dimers” in the photoreceptors. Vitamin A dimers are believed to be partially responsible for vision loss.

While vitamin A dimerization occurs in people without STGD1 as well, the process is accelerated in STGD1 and dimers take only a few years rather than decades to accumulate.

Learn More About ALK-001 Clinical Trials »

Stargardt Disease Mailing List

If you have Stargardt disease and want to stay informed about our research, please complete the following form below. As Stargardt disease is very rare, the information below will help us better understand the disease.

No identifiable information (such as name, email or phone number) will be disclosed to any 3rd party. We will use your information to contact you or your physician about upcoming trials.

If you know anyone else with Stargardt disease, please let them know about our research.

  • At what age did you start having visual trouble ?

  • Back then, what was the vision of your best seeing eye (20/xxx)? If you do not know the numbers, use your own words to describe your vision ("good", "bad", "ok", what you could or couldn't see)

  • What is your vision today (best seeing eye, 20/xxx)?
  • First Name
  • Last Name
  • Zip Code
  • Country
  • City
  • How old are you today?
  • Telephone
  • Email
  • Have you been genetically confirmed for Stargardt (Yes/No)?
  • If yes, please provide the detected ABCA4 genetic mutation(s)
  • Name of your ophthalmologist
  • Contact information of your ophthalmologist (phone, email or both)
  • If you are under 18 years old, please enter the name of a parent or legal representative:
  • If you filled out this form for someone else, please enter your name here

    Alkeus Pharma takes your personal information seriously. The information you provide will only be used by Alkeus Pharma to send you additional questions, updates on trials, or other helpful news on Stargardt disease trials and research.

    To be removed from our database, please email us at info@alkeus.com

    By submitting this form you agree to the terms: (1) There is no guarantee you will be enrolled in any clinical trial, (2) There is no guarantee that there ever will be a clinical trial, and (3) You authorize Alkeus Pharma and parties acting on its behalf to contact you.